PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1 α axis.
CONCLUSION: PARP1 inhibitor INO1001 attenuated cardiomyopathic features in diabetic mice through the activation of SIRT1 and its downstream antioxidant defence mechanisms. The results of this study suggest a pivotal role of PARP-1 inhibition in treating diabetic and AT-induced cardiomyopathy.
PMID: 30359575 [PubMed - as supplied by publisher]
Source: Experimental Cell Research - Category: Cytology Authors: Waldman M, Nudelman V, Shainberg A, Abraham NG, Dan Aravot, Arad M, Hochhauser E Tags: Exp Cell Res Source Type: research
More News: Antidoxidants | Cardiology | Cardiomyopathy | Cytology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Gastroschisis Repair | Heart | Heart Failure | Hypertension | Obesity | Perinatology & Neonatology | Science | Study